Penumbra's THUNDERBOLT Receives FDA Clearance as First Computer-Assisted Vacuum Thrombectomy Device for Acute Ischemic Stroke
Key Insights
Penumbra received FDA clearance for THUNDERBOLT (search), the first computer-assisted vacuum thrombectomy (CAVT) platform designed for acute ischemic stroke (search) treatment.
The device introduces modulated aspiration technology that detects, fatigues, and completely ingests clots at the occlusion site, enabling faster and more complete clot removal.
The clearance represents a positive milestone for Boston Scientific, which agreed to acquire Penumbra for approximately $14.5 billion in January 2026.
Penumbra, Inc. (search) announced Thursday it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT (search), a first-of-its-kind computer-assisted vacuum thrombectomy (CAVT) platform designed to treat acute ischemic stroke (search). The clearance marks a significant advancement in neurovascular intervention, introducing modulated aspiration technology that aims to enable faster, more complete clot removal in stroke patients.
The regulatory milestone also represents a positive development for Boston Scientific, which agreed to acquire Penumbra for approximately $14.5 billion in January 2026 to expand its presence in the mechanical thrombectomy and neurovascular markets. Penumbra shareholders approved the sale in May, and Boston Scientific expects to close the acquisition later this year.
A Novel Approach to Stroke Thrombectomy
THUNDERBOLT (search) is powered by the Penumbra ENGINE and introduces modulated aspiration to the company's neuro thrombectomy portfolio. The CAVT technology is designed to detect, fatigue, and completely ingest clot at the site of the occlusion — a departure from conventional aspiration thrombectomy approaches.
"Modulated aspiration may facilitate more consistent and complete clot removal when used in conjunction with standard aspiration thrombectomy catheters," said David Fiorella, MD, PhD, director of the Cerebrovascular Center at Stony Brook University Hospital. "Our early experience with THUNDERBOLT (search) within the context of the trial suggests that this technology will meaningfully change how we approach stroke treatment, and could substantively improve outcomes in patients with emergent large vessel occlusion (search)."
Donald Frei, M.D., neurointerventional radiologist at Swedish Medical Center in Denver, Colorado, emphasized the clinical urgency the device addresses: "Stroke is the second leading cause of death worldwide and with stroke, timing is critical. If the blood clot isn't removed and the artery reopened quickly, patients can face severe disability or even death." He added that THUNDERBOLT (search)'s innovative design "minimizes catheter manipulation and promotes safe, complete clot capture — quickly restoring blood flow to the brain and giving patients the best chance at recovery."
The Stroke Treatment Landscape
A recent analysis estimates that stroke mortality worldwide is projected to increase by 50% between 2020 and 2050. In the United States, someone suffers from a stroke every 40 seconds, and one in every 21 people dies from the condition. As the only CAVT device available for stroke treatment in the U.S., THUNDERBOLT (search) represents a first-of-its-kind advancement in acute ischemic stroke (search) care.
"Penumbra was founded to redefine stroke care and THUNDERBOLT (search) delivers on that promise," said Shruthi Narayan, president of Penumbra. "We are uniquely positioned as the only company offering CAVT technology across both vascular and neurovascular conditions — redefining blood clot care from head-to-toe."
Market Implications and Analyst Perspective
The FDA clearance was met with relief from Wall Street analysts who had been monitoring the device's progress. The THUNDERBOLT (search) technology faced delays in its journey to market when its clinical trial ran behind schedule and the FDA requested a change to the study's endpoint.
"Investors have been waiting for a long time for this approval," Evercore ISI analyst Vijay Kumar wrote to clients. "It is good to see this come through and allays concerns of any potential issues with the data." Kumar estimated that THUNDERBOLT (search) could contribute approximately $100 million in incremental revenue to Boston Scientific over time.
Product Configuration
THUNDERBOLT (search) will be pre-packaged with one of Penumbra's market-leading catheters — RED 62, RED 68, RED 72 SILVER LABEL, or RED 72 SILVER LABEL with SENDit technology — providing clinicians with an integrated thrombectomy solution at the point of care.